↓ Skip to main content

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

Overview of attention for article published in The Journal of Headache and Pain, September 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
5 news outlets
policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Published in
The Journal of Headache and Pain, September 2018
DOI 10.1186/s10194-018-0918-3
Pubmed ID
Authors

Michail Vikelis, Andreas A. Argyriou, Emmanouil V. Dermitzakis, Konstantinos C. Spingos, Nikolaos Makris, Evangelia Kararizou

Abstract

Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term treatment is still limited. We herein aimed at assessing whether there is a sustained benefit and good safety with repeated onabotulinumtoxinA sessions in CM over more than three years of treatment. We prospectively enrolled 65 CM patients, who were classified as responders after three sessions of onabotulinumtoxinA and were eligible to further continue treatment. Data documenting longitudinal changes from the trimester after the third onabotulinumtoxinA administration (T1) to the trimester after completing two years of treatment (T2) and eventually to the trimester after completing three years of treatment (T3) in (i) mean number of monthly headache days (ii) migraine severity as expressed by the mean number of days with peak headache intensity of > 4/10, and (iii) mean number of days with use of any acute headache medication, were prospectively collected from patients' headache diaries. A total of 56 (86.1%) of 65 patients achieved to attain onabotulinumtoxinA over three years. At T3, a significant reduction in mean monthly headache days was evident, compared to T1 (3.4 ± 1.7 vs 7.2 ± 3.8; P < 0.001) with diminished mean number of monthly days with peak headache intensity of more than 4/10 and a significant change in days using acute headache medications per month between T1 and T3 (2.8 ± 1.3 vs 4.7 ± 3.2; P < 0.001). Significant changes were also noticed in all efficacy variables from T2 to T3. Therapy was safe and well tolerated with low rates of adverse events or drop-outs. The long -term treatment with onabotulinumtoxinA proved effective, safe and well tolerated over three years. Our findings support the strategy to consistently deliver sessions of use of onabotulinumtoxinΑ over long time in CM patients (Trial registration NTC03606356, registered retrospectively, 28 July 2018).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 15%
Researcher 5 13%
Student > Bachelor 4 10%
Unspecified 3 8%
Student > Ph. D. Student 3 8%
Other 6 15%
Unknown 13 33%
Readers by discipline Count As %
Medicine and Dentistry 11 28%
Nursing and Health Professions 3 8%
Unspecified 3 8%
Agricultural and Biological Sciences 2 5%
Neuroscience 2 5%
Other 5 13%
Unknown 14 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2022.
All research outputs
#855,395
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#85
of 1,417 outputs
Outputs of similar age
#19,700
of 343,209 outputs
Outputs of similar age from The Journal of Headache and Pain
#3
of 40 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,209 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.